Asbmr

All abstracts from the meeting will be published in Journal of Bone and Mineral Research (the official journal of the American Society for Bone and Mineral Research) volume 28 [Suppl. 1]. The American Society for Bone and Mineral Research (ASBMR) held its annual conference in Seattle, WA, 9–12 October 2015. This report covers some highlights of key presentations on osteoporosis therapeutics. Printer friendly Email Share Tweet Like These Congress Highlights are based on the abstracts presented at the ASBMR 2015 Annual Meeting of the American Society for Bone and Mineral Research.

Entera presented the results of its Phase 2a clinical study. This report was compiled from the Clinical Science Meeting Overview at the American Society for Bone and Mineral Research (ASBMR) conference in Seattle, WA, 9–12 October 2015. An initial draft was prepared by GM with clinical verification/input by DR and a final draft prepared together. Our aim has been to condense the material as a starting point for further reading. Cited references include some given during the presentations, but others have been added for clarification.

The long-term follow studies with denosumab give comfort that treatment up to 10 years will show continued benefits in terms of bone mass and structural changes with, in all likelihood, maintained antifracture efficacy. Studies presented examining the potential for the antiresorptive agents, odanacatib and abaloparatide, suggest that these new treatments may well have a role in the clinic very soon when approved by licensing authorities in the USA and Europe. There may well be new anabolic therapies to follow into clinic, with the most advanced of these in terms of clinical investigation being the antisclerostin antibody, romosuzumab, early data from which is showing very encouraging results.

All information contained on this page is embargoed. Media are required to abide by the embargo policies governing the ASBMR 2015 Annual Meeting.The embargo policystates that coverage of research being presented at the Annual Meeting is strictly prohibited until one hour after the presentation concludes. This includes abstracts highlighted as part of the official media kit and those published in the ASBMR official journal, theJournal of Bone and Mineral Research(JBMRAbstracts book) and made available to media through the web-based abstracts program and itinerary builder.

Information contained here supersedes all prior versions of the ASBMR 2015 Annual Meeting abstracts in all forms, including the onsite program book and the abstract book. The complete Annual Meeting Abstracts from 2015 are available here and are fully citable as an electronic supplement to the Journal of Bone and Mineral Research. From this site, you can search and click on the desired abstract.

Bone mineral density (BMD) measurement in patients on osteoporosis treatment may be a predictor of fracture risk, and a specific T score should be further evaluated as a practical goal for therapy. These were the conclusions made by Dr Serge Ferrari (Geneva University Hospital, Switzerland) and colleagues at a presentation of a study where they investigated the relationship between BMD T score and fracture risk during osteoporosis treatment with denosumab [Ferrari et al. 2015]. For more information, or to arrange interviews with presenters or ASBMR leadership, please contact Amanda Darvill at [email protected] She can be reached in advance of the ASBMR Annual Meeting on +1.202.367.2302 or during the meeting at +1.202.316.4141. This online resource includes information for media attending the ASBMR 2015 Annual Meeting in person and we will also be posting resources for media that are unable to attend but would like to cover the meeting remotely.

Entera presented the results of its Phase 2a clinical study. This report was compiled from the Clinical Science Meeting Overview at the American Society for Bone and Mineral Research (ASBMR) conference in Seattle, WA, 9–12 October 2015. An initial draft was prepared by GM with clinical verification/input by DR and a final draft prepared together. Our aim has been to condense the material as a starting point for further reading. Cited references include some given during the presentations, but others have been added for clarification.

Please be aware that abstracts submitted to the ASBMR Annual Meeting are ed by the American Society for Bone and Mineral Research and published in theJBMR. Reproduction, distribution, or transmission of the abstracts in whole or in part, by electronic, mechanical or other means, or other intended use, is prohibited without the express written permission of the American Society for Bone and Mineral Research. Information about how to obtain permission to re-use ASBMR Annual Meeting abstracts is provided on the ASBMR website. Dr. Melita Irving, the clinical geneticist who is coordinating the phase 2 clinical trial of BMN-111 in London, presented at the American Society for Bone and Mineral Research Annual 2015 Meeting (ASBMR) the initial six-month data from the first three cohorts of a Phase 2 proof-of-concept and dose-finding study of vosoritide (BMN 111). The selected abstracts from the ASBMR 2015 demonstrate that further therapeutic advances are continuing in the management of osteoporosis.

The full abstract will open. You can then copy the URL address and paste it to your citation (see example below).

Brussels, Belgium, 8th October, 2015 - UCB today announced that it will present data from multiple studies for investigational molecule romosozumab at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Seattle on Oct. 9-12, 2015. In addition, osteoporosis disease-state presentations will provide key insights around unmet needs among patients at high risk for fracture, and the potentially serious consequences of inadequate osteoporosis treatment. October 2015 - Entera presents the "Oral PTH (1-34) in the Treatment of Hypoparathyroidism" for its hypoparathyroidism drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Seattle, Washington. Primary hypoparathyroidism (PHP) is a hormone deficiency for which no oral replacement therapy is currently available. Oral PTH administration may allow for more flexibility in providing an adequate therapeutic dose, for achievement of normocalemia and normophosphatemia in patients with varied severity of hormone deficiency and response to therapy.

Information contained here supersedes all prior versions of the ASBMR 2015 Annual Meeting abstracts in all forms, including the onsite program book and the abstract book. The complete Annual Meeting Abstracts from 2015 are available here and are fully citable as an electronic supplement to the Journal of Bone and Mineral Research. From this site, you can search and click on the desired abstract.

All information contained on this page is embargoed. Media are required to abide by the embargo policies governing the ASBMR 2015 Annual Meeting.The embargo policystates that coverage of research being presented at the Annual Meeting is strictly prohibited until one hour after the presentation concludes. This includes abstracts highlighted as part of the official media kit and those published in the ASBMR official journal, theJournal of Bone and Mineral Research(JBMRAbstracts book) and made available to media through the web-based abstracts program and itinerary builder.

Bone mineral density (BMD) measurement in patients on osteoporosis treatment may be a predictor of fracture risk, and a specific T score should be further evaluated as a practical goal for therapy. These were the conclusions made by Dr Serge Ferrari (Geneva University Hospital, Switzerland) and colleagues at a presentation of a study where they investigated the relationship between BMD T score and fracture risk during osteoporosis treatment with denosumab [Ferrari et al. 2015]. For more information, or to arrange interviews with presenters or ASBMR leadership, please contact Amanda Darvill at [email protected] She can be reached in advance of the ASBMR Annual Meeting on +1.202.367.2302 or during the meeting at +1.202.316.4141. This online resource includes information for media attending the ASBMR 2015 Annual Meeting in person and we will also be posting resources for media that are unable to attend but would like to cover the meeting remotely.

Please be aware that abstracts submitted to the ASBMR Annual Meeting are ed by the American Society for Bone and Mineral Research and published in theJBMR. Reproduction, distribution, or transmission of the abstracts in whole or in part, by electronic, mechanical or other means, or other intended use, is prohibited without the express written permission of the American Society for Bone and Mineral Research. Information about how to obtain permission to re-use ASBMR Annual Meeting abstracts is provided on the ASBMR website. Dr. Melita Irving, the clinical geneticist who is coordinating the phase 2 clinical trial of BMN-111 in London, presented at the American Society for Bone and Mineral Research Annual 2015 Meeting (ASBMR) the initial six-month data from the first three cohorts of a Phase 2 proof-of-concept and dose-finding study of vosoritide (BMN 111). The selected abstracts from the ASBMR 2015 demonstrate that further therapeutic advances are continuing in the management of osteoporosis.

All abstracts from the meeting will be published in Journal of Bone and Mineral Research (the official journal of the American Society for Bone and Mineral Research) volume 28 [Suppl. 1]. The American Society for Bone and Mineral Research (ASBMR) held its annual conference in Seattle, WA, 9–12 October 2015. This report covers some highlights of key presentations on osteoporosis therapeutics. Printer friendly Email Share Tweet Like These Congress Highlights are based on the abstracts presented at the ASBMR 2015 Annual Meeting of the American Society for Bone and Mineral Research.

The long-term follow studies with denosumab give comfort that treatment up to 10 years will show continued benefits in terms of bone mass and structural changes with, in all likelihood, maintained antifracture efficacy. Studies presented examining the potential for the antiresorptive agents, odanacatib and abaloparatide, suggest that these new treatments may well have a role in the clinic very soon when approved by licensing authorities in the USA and Europe. There may well be new anabolic therapies to follow into clinic, with the most advanced of these in terms of clinical investigation being the antisclerostin antibody, romosuzumab, early data from which is showing very encouraging results.

All information contained on this page is embargoed. Media are required to abide by the embargo policies governing the ASBMR 2015 Annual Meeting.The embargo policystates that coverage of research being presented at the Annual Meeting is strictly prohibited until one hour after the presentation concludes. This includes abstracts highlighted as part of the official media kit and those published in the ASBMR official journal, theJournal of Bone and Mineral Research(JBMRAbstracts book) and made available to media through the web-based abstracts program and itinerary builder.

Bone mineral density (BMD) measurement in patients on osteoporosis treatment may be a predictor of fracture risk, and a specific T score should be further evaluated as a practical goal for therapy. These were the conclusions made by Dr Serge Ferrari (Geneva University Hospital, Switzerland) and colleagues at a presentation of a study where they investigated the relationship between BMD T score and fracture risk during osteoporosis treatment with denosumab [Ferrari et al. 2015]. For more information, or to arrange interviews with presenters or ASBMR leadership, please contact Amanda Darvill at [email protected] She can be reached in advance of the ASBMR Annual Meeting on +1.202.367.2302 or during the meeting at +1.202.316.4141. This online resource includes information for media attending the ASBMR 2015 Annual Meeting in person and we will also be posting resources for media that are unable to attend but would like to cover the meeting remotely.

Brussels, Belgium, 8th October, 2015 - UCB today announced that it will present data from multiple studies for investigational molecule romosozumab at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Seattle on Oct. 9-12, 2015. In addition, osteoporosis disease-state presentations will provide key insights around unmet needs among patients at high risk for fracture, and the potentially serious consequences of inadequate osteoporosis treatment. October 2015 - Entera presents the "Oral PTH (1-34) in the Treatment of Hypoparathyroidism" for its hypoparathyroidism drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Seattle, Washington. Primary hypoparathyroidism (PHP) is a hormone deficiency for which no oral replacement therapy is currently available. Oral PTH administration may allow for more flexibility in providing an adequate therapeutic dose, for achievement of normocalemia and normophosphatemia in patients with varied severity of hormone deficiency and response to therapy.

Entera presented the results of its Phase 2a clinical study. This report was compiled from the Clinical Science Meeting Overview at the American Society for Bone and Mineral Research (ASBMR) conference in Seattle, WA, 9–12 October 2015. An initial draft was prepared by GM with clinical verification/input by DR and a final draft prepared together. Our aim has been to condense the material as a starting point for further reading. Cited references include some given during the presentations, but others have been added for clarification.

The full abstract will open. You can then copy the URL address and paste it to your citation (see example below).

The long-term follow studies with denosumab give comfort that treatment up to 10 years will show continued benefits in terms of bone mass and structural changes with, in all likelihood, maintained antifracture efficacy. Studies presented examining the potential for the antiresorptive agents, odanacatib and abaloparatide, suggest that these new treatments may well have a role in the clinic very soon when approved by licensing authorities in the USA and Europe. There may well be new anabolic therapies to follow into clinic, with the most advanced of these in terms of clinical investigation being the antisclerostin antibody, romosuzumab, early data from which is showing very encouraging results.

Information contained here supersedes all prior versions of the ASBMR 2015 Annual Meeting abstracts in all forms, including the onsite program book and the abstract book. The complete Annual Meeting Abstracts from 2015 are available here and are fully citable as an electronic supplement to the Journal of Bone and Mineral Research. From this site, you can search and click on the desired abstract.

All abstracts from the meeting will be published in Journal of Bone and Mineral Research (the official journal of the American Society for Bone and Mineral Research) volume 28 [Suppl. 1]. The American Society for Bone and Mineral Research (ASBMR) held its annual conference in Seattle, WA, 9–12 October 2015. This report covers some highlights of key presentations on osteoporosis therapeutics. Printer friendly Email Share Tweet Like These Congress Highlights are based on the abstracts presented at the ASBMR 2015 Annual Meeting of the American Society for Bone and Mineral Research.

Bone mineral density (BMD) measurement in patients on osteoporosis treatment may be a predictor of fracture risk, and a specific T score should be further evaluated as a practical goal for therapy. These were the conclusions made by Dr Serge Ferrari (Geneva University Hospital, Switzerland) and colleagues at a presentation of a study where they investigated the relationship between BMD T score and fracture risk during osteoporosis treatment with denosumab [Ferrari et al. 2015]. For more information, or to arrange interviews with presenters or ASBMR leadership, please contact Amanda Darvill at [email protected] She can be reached in advance of the ASBMR Annual Meeting on +1.202.367.2302 or during the meeting at +1.202.316.4141. This online resource includes information for media attending the ASBMR 2015 Annual Meeting in person and we will also be posting resources for media that are unable to attend but would like to cover the meeting remotely.

The long-term follow studies with denosumab give comfort that treatment up to 10 years will show continued benefits in terms of bone mass and structural changes with, in all likelihood, maintained antifracture efficacy. Studies presented examining the potential for the antiresorptive agents, odanacatib and abaloparatide, suggest that these new treatments may well have a role in the clinic very soon when approved by licensing authorities in the USA and Europe. There may well be new anabolic therapies to follow into clinic, with the most advanced of these in terms of clinical investigation being the antisclerostin antibody, romosuzumab, early data from which is showing very encouraging results.

Information contained here supersedes all prior versions of the ASBMR 2015 Annual Meeting abstracts in all forms, including the onsite program book and the abstract book. The complete Annual Meeting Abstracts from 2015 are available here and are fully citable as an electronic supplement to the Journal of Bone and Mineral Research. From this site, you can search and click on the desired abstract.

The full abstract will open. You can then copy the URL address and paste it to your citation (see example below).

All information contained on this page is embargoed. Media are required to abide by the embargo policies governing the ASBMR 2015 Annual Meeting.The embargo policystates that coverage of research being presented at the Annual Meeting is strictly prohibited until one hour after the presentation concludes. This includes abstracts highlighted as part of the official media kit and those published in the ASBMR official journal, theJournal of Bone and Mineral Research(JBMRAbstracts book) and made available to media through the web-based abstracts program and itinerary builder.

Brussels, Belgium, 8th October, 2015 - UCB today announced that it will present data from multiple studies for investigational molecule romosozumab at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Seattle on Oct. 9-12, 2015. In addition, osteoporosis disease-state presentations will provide key insights around unmet needs among patients at high risk for fracture, and the potentially serious consequences of inadequate osteoporosis treatment. October 2015 - Entera presents the "Oral PTH (1-34) in the Treatment of Hypoparathyroidism" for its hypoparathyroidism drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Seattle, Washington. Primary hypoparathyroidism (PHP) is a hormone deficiency for which no oral replacement therapy is currently available. Oral PTH administration may allow for more flexibility in providing an adequate therapeutic dose, for achievement of normocalemia and normophosphatemia in patients with varied severity of hormone deficiency and response to therapy.

Please be aware that abstracts submitted to the ASBMR Annual Meeting are ed by the American Society for Bone and Mineral Research and published in theJBMR. Reproduction, distribution, or transmission of the abstracts in whole or in part, by electronic, mechanical or other means, or other intended use, is prohibited without the express written permission of the American Society for Bone and Mineral Research. Information about how to obtain permission to re-use ASBMR Annual Meeting abstracts is provided on the ASBMR website. Dr. Melita Irving, the clinical geneticist who is coordinating the phase 2 clinical trial of BMN-111 in London, presented at the American Society for Bone and Mineral Research Annual 2015 Meeting (ASBMR) the initial six-month data from the first three cohorts of a Phase 2 proof-of-concept and dose-finding study of vosoritide (BMN 111). The selected abstracts from the ASBMR 2015 demonstrate that further therapeutic advances are continuing in the management of osteoporosis.

Entera presented the results of its Phase 2a clinical study. This report was compiled from the Clinical Science Meeting Overview at the American Society for Bone and Mineral Research (ASBMR) conference in Seattle, WA, 9–12 October 2015. An initial draft was prepared by GM with clinical verification/input by DR and a final draft prepared together. Our aim has been to condense the material as a starting point for further reading. Cited references include some given during the presentations, but others have been added for clarification.